A5004228804- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease and Transplantation
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Hepatitis C virus research
- Colorectal Cancer Treatments and Studies
- Hepatitis B Virus Studies
- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Liver Diseases and Immunity
- Lung Cancer Treatments and Mutations
- Liver physiology and pathology
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Organ Transplantation Techniques and Outcomes
- Systemic Lupus Erythematosus Research
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Inflammatory Biomarkers in Disease Prognosis
- Viral-associated cancers and disorders
- Radiomics and Machine Learning in Medical Imaging
University Medical Center of the Johannes Gutenberg University Mainz
2016-2025
Johannes Gutenberg University Mainz
2016-2025
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
2014-2025
München Klinik
2024
University of Applied Sciences Mainz
2022
Medical University of Vienna
2022
National Cancer Registry
2019
Sana Klinikum Lichtenberg
2017
Universitätsmedizin Göttingen
2017
Charité - Universitätsmedizin Berlin
2017
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
Purpose Gemcitabine is standard of care in the adjuvant treatment resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib combination with gemcitabine has shown efficacy advanced PDAC and was considered to improve survival patients primarily after R0 resection. Patients Methods In an open-label, multicenter trial, were randomly assigned one two study arms: 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus 100 mg once per day...
The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection early-stage HCC in patients with NASH have limitations. We assessed the ability GALAD score, which determines risk based on patient sex; age; and serum levels α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), des-gamma-carboxy prothrombin (DCP), to detect NASH.We performed a case-control study 125 (20% within Milan Criteria) 231 without (NASH controls)...
•Baseline serum AFP ≥100 ng/ml and CRP ≥1 mg/dl were independently associated with worse OS in ICB-treated patients HCC.•A score based on these two variables predicts disease control rate overall survival HCC.•The was validated an independent cohort of HCC.•In sorafenib-treated HCC, the prognostic for but not predictive rate. Background & AimsImmunotherapy atezolizumab plus bevacizumab represents new standard care systemic front-line treatment hepatocellular carcinoma (HCC). However,...
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment unresectable HCC. No evidence exists as to its use in routine clinical practice patients with impaired liver function.
Although the pathomechanisms of autoimmune diseases in various organs remain unresolved, an accumulation individual patients has been observed. An overlap hepatitis (AIH) and primary biliary cirrhosis (PBC) or sclerosing well documented. However, other than PBC PSC not yet investigated a large cohort.The goal our analysis was to investigate incidence concurrent with AIH.We analyzed cohort 278 AIH for diseases.A total 111 (40%) were diagnosed additional diseases. Besides syndromes PSC,...
Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib alters HCC by restoring classical macrophage polarization triggering tumor-directed natural killer (NK) cell In vivo experiments were conducted with (25 mg/kg)-treated C57BL/6 wildtype as well hepatitis B virus (HBV) lymphotoxin transgenic mice without HCC. Monocyte-derived Mϕ or tumor-associated (TAM) isolated from tissue...
The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences in HCC, particularly LCI B/C, where only limited data are available regard to safety efficacy of sorafenib.Thirty-four HCC were treated regardless function prior anticancer therapy. Adverse events (AEs) graded using Common Toxicity Criteria version 3.0, tumor response was assessed according Response...
To compare the overall survival of patients with hepatocellular carcinoma (HCC) who were treated lipiodol-based conventional transarterial chemoembolization (cTACE) that drug-eluting bead (DEB-TACE). By an electronic search our radiology information system, we identified 674 received TACE between November 2002 and July 2013. A total 520 cTACE, 154 DEB-TACE. In total, 424 excluded for following reasons: tumor type other than HCC (n = 91), liver transplantation after 119), lack histological...
Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.To evaluate safety and efficacy nivolumab pembrolizumab an international, multicentre, real-world cohort patients with advanced carcinoma.Sixty-five treated (n = 34) or 31) between July 10, 2015 December 31, 2018 (data cut-off) across six centres Austria Germany were retrospectively analysed.Child-Pugh class A/B/C was 32 (49%)/28 (43%)/5 (8%). Immunotherapy used...
To prospectively compare SIRT and DEB-TACE for treating hepatocellular carcinoma (HCC). From 04/2010–07/2012, 24 patients with histologically proven unresectable N0, M0 HCCs were randomized 1:1 to receive or DEB-TACE. could be repeated once in case of recurrence; while, TACE was every 6 weeks until no viable tumor tissue detected by MRI contraindications prohibited further treatment. Patients followed-up 3 months; the final evaluation 05/2013. Both groups comparable demographics (SIRT:...
The incidence of non-alcoholic steatohepatitis (NASH) is increasing worldwide and a poorly defined subset patients develops end-stage liver disease hepatocellular carcinoma (HCC). Differences in the biological behaviour, tumour characteristics, associated risk factors, treatment outcomes overall survival with NASH-HCC remain defined. aim this study was to determine analyze these differences large clinical cohort guide decisions. 1119 HCC treated an 11 year period at University Medical Centre...
Die interdisziplinäre Leitlinie der Qualität S3 zur Diagnose und Therapie des hepatozellulären Karzinoms (HCC) ist ein evidenz- konsensbasiertes Instrument, um die Diagnostik HCC zu verbessern, da äußerst diffiziles Vorgehen erfordert. Es Aufgabe Leitlinie, dem Patienten (mit Verdacht auf oder nachgewiesenem HCC) angemessene, wissenschaftlich begründete aktuelle Verfahren in Diagnostik, Rehabilitation anzubieten. Dies gilt sowohl für lokal begrenzte fortgeschrittene Erkrankung als auch bei...
Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes regorafenib as HCC recurrence after liver transplantation (LT). This a retrospective, multicenter, international study including regorafenib-treated LT (2015-2018), with analysis baseline characteristics evolutionary events during sorafenib/regorafenib treatment. Twenty-eight (57...
Evaluation of the efficacy and safety atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function prior systemic therapy.
The aim of this study was to analyze clinical presentation, course disease, and management patients with hepatocellular carcinoma (HCC) in a German referral center between 1998 2009.HCC is rare tumor Germany, but its incidence has increased over the last 30 years. New therapies such as chemoembolization drug-eluting beads, selective internal radiotherapy, sorafenib were introduced recently; however, impact on overall survival (OS) unclear.In retrospective analysis, 1066 HCC, separated into...
The BCLC-staging system is used to facilitate treatment decisions in patients with hepatocellular carcinoma (HCC). Owing the observed clinical heterogeneity of intermediate stage BCLC-B, a subclassification was proposed taking Child-Pugh score and extended criteria for transplantation into account. Analysis prognostic significance BCLC-B European cohort HCC patients.Eight hundred eighty four consecutive were retrospectively analysed. Patients grouped according subclassification. Baseline...
Abstract Background & Aims Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree PVTT varies from sub‐/segmental invasion to complete occlusion main trunk. Aim this study was evaluate whether correlates prognosis. Methods A total 1317 HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. diagnosed by contrast‐enhanced computed tomography or magnetic resonance...
Hepatocellular carcinoma (HCC) is one of the most lethal cancers. Nutrition- and life style-associated risk factors are increasingly prevalent. Metformin, mainstay type 2 diabetes mellitus (T2DM)-treatment, reduces hepatocarcinogenesis. However, its influence on prognosis patients with HCC has not been investigated a large scale, yet.Five thousand ninety-three treated for between 2000 2016 at three referral centres were included in this retrospective multicentre study. The aim study was to...
The novel CRP-albumin-lymphocyte (CALLY) index is an improved immunonutritive scoring system, based on serum C-reactive protein (CRP), albumin, and the lymphocyte count. It has shown promise as a prognostic for patients with hepatocellular carcinoma (HCC) undergoing resections. This study evaluated ability of CALLY HCC transarterial chemoembolization (TACE). We retrospectively identified 280 treatment-naïve that underwent initial TACE at our institution, between 2010 2020. compared to...
Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world insufficiently defined. purpose this study was to evaluate the a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis 205 treated systemic at 14 different sites conducted. Overall survival, progression free overall response rate adverse event rates were assessed analyzed. Results...